Wedbush Has Positive Outlook of NBIX FY2027 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Analysts at Wedbush upped their FY2027 EPS estimates for Neurocrine Biosciences in a research note issued on Monday, December 23rd. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of $14.46 for the year, up from their prior forecast of $13.11. Wedbush has a “Outperform” rating and a $148.00 price objective on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.94 per share. Wedbush also issued estimates for Neurocrine Biosciences’ FY2028 earnings at $17.74 EPS.

NBIX has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 16th. William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. BMO Capital Markets decreased their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Piper Sandler reaffirmed an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a report on Monday. Finally, Raymond James reissued an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $166.29.

Neurocrine Biosciences Trading Down 0.3 %

Shares of NASDAQ NBIX opened at $136.53 on Wednesday. Neurocrine Biosciences has a 12-month low of $110.95 and a 12-month high of $157.98. The company has a market cap of $13.82 billion, a price-to-earnings ratio of 36.60 and a beta of 0.34. The stock’s 50 day simple moving average is $124.79 and its 200 day simple moving average is $130.60.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now owns 2,507 shares of the company’s stock, valued at $338,445. The trade was a 30.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the transaction, the insider now owns 15,449 shares in the company, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of NBIX. Tri Ri Asset Management Corp bought a new stake in Neurocrine Biosciences in the third quarter worth approximately $3,236,000. Tidal Investments LLC lifted its position in shares of Neurocrine Biosciences by 52.8% during the 3rd quarter. Tidal Investments LLC now owns 15,043 shares of the company’s stock worth $1,733,000 after purchasing an additional 5,197 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Neurocrine Biosciences in the third quarter valued at approximately $384,000. Sanctuary Advisors LLC grew its position in Neurocrine Biosciences by 103.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 7,649 shares of the company’s stock worth $961,000 after purchasing an additional 3,898 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Neurocrine Biosciences during the third quarter valued at about $1,985,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.